Price movement over the last 24 hours
Agilent Technologies Inc vs Appian Corp — how do they compare? Agilent Technologies Inc trades at $128.69 (market cap $37.04B), while Appian Corp trades at $24.26 (market cap $1.81B). The key difference: Agilent Technologies Inc is far larger — about 20.5× Appian Corp's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| A | APPN | |
|---|---|---|
Market Cap | $37.04B | $1.81B |
Sector | Health | Technology |
52-Week High | $157.20 | $45.64 |
52-Week Low | $110.24 | $18.72 |
Enterprise Value | $38.59B | $1.90B |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Appian (APPN) trades at $24.68, up 1.15% with bullish technical signals from moving averages. The company shows strong revenue growth reaching $727M in 2025 and has beaten earnings estimates for three consecutive quarters. However, profitability remains minimal with a net margin of just 0.12% and negative shareholder equity of -$32.64M. Recent CEO stock sales and mixed analyst sentiment create uncertainty despite positive AI-driven business developments.
Appian presents a growth story with improving cash flow and AI positioning, but faces significant profitability challenges and negative equity. The stock trades near analyst consensus target of $26.20, suggesting limited upside. Key risks include sustained unprofitability and high debt levels, while opportunities lie in enterprise AI adoption and cloud revenue growth.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →